In this study, we reviewed the safety and efficacy of botulinum toxin type A (BoNT-A)
injection with respect to motor development in children with spastic cerebral palsy aged< 2 …

This retrospective study aimed to examine the safety of botulinum toxin A (BoNT-A)
treatment in a paediatric multidisciplinary cerebral palsy clinic. In a sample of 454 patients …

Botulinum neurotoxin type‐A (BoNT‐A) has been used in association with other
interventions in the management of spasticity in children with cerebral palsy (CP) for almost …

Botulinum toxin type A (BoNT-A) therapy has gained wide acceptance in the management of
spasticity in cerebral palsy (CP). Clinical experience from numerous case reports and series …

Objective: To assess the safety of botulinum toxin type A for children with cerebral palsy
using data from randomized clinical trials. Data sources: A search was conducted of …

Aim The aim of this study was to determine the effects of repeat botulinum toxin A (Bo NT‐A)
injections in children with spastic cerebral palsy (CP) on the basis of a best evidence …

Botulinum toxin A (BoNT-A) is considered a safe and effective therapy for children with
cerebral palsy (CP), especially in the hands of experienced injectors and for the majority of …

Aim Previous studies have shown the efficacy of botulinum toxin type A (BoNT‐A) in the
management of ambulant individuals with cerebral palsy (CP). There is little evidence on its …

Management of children with cerebral palsy (CP) is the focus of considerable resources in
many countries, so that evaluation of the efficacy for new and established treatments is …

Abstract Background Botulinum toxin A (BTX-A) has been successfully used as a treatment
for children with spastic cerebral palsy; however, the effect of BTX-A on reducing spasticity …